Black Rock Inc. Inhibikase Therapeutics, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.63 - $1.44 $32,443 - $74,155	-51,497 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.03 - $1.77 $2,623 - $4,508	-2,547 Reduced 4.71%	51,497 $76,000
Q4 2021 Feb 10, 2022	BUY	$1.38 - $2.17 $4,558 - $7,167	3,303 Added 6.51%	54,044 $79,000
Q3 2021 Nov 09, 2021	BUY	$1.79 - $2.81 $66,534 - $104,447	37,170 Added 273.89%	50,741 $96,000
Q2 2021 Aug 11, 2021	BUY	$2.8 - $6.23 $37,998 - $84,547	13,571 New	13,571 $38,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $30.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.